Drug Analysis Service and Cannabis Laboratory

Health Canada’s Drug Analysis Service and Cannabis Laboratory analyze drugs and substances submitted by Canadian law enforcement and public health officials.

  • Last updated: 2024-10-18

By making this framework and substance classification list available online, Health Canada's Drug Analysis Service and Cannabis Laboratory (HC DAS and CL) aims to support the efforts of public health professionals, forensic scientists and data specialists to better integrate timely drug analysis results generated by their laboratories, into their surveillance systems, for routine monitoring and early warning purposes.HC DAS and CL developed this evidence-based classification framework for psychoactive substances to align with the work of partners from the United States’ White House Office of National Drug Control Policy (ONDCP), U.S. Customs and Border Protection (CBP), the European Union Drugs Agency (EUDA), and the United Nations Office on Drugs and Crime (UNODC).

Method for substance classification

To classify individual substances, the HC DAS and CL reviewed existing pharmacological classification frameworks from ONDCP, EUDA and UNODC. Differences in classification frameworks were resolved, and new classes were introduced to capture previously uncategorized psychoactive substances of public health concern and to improve the granularity of the classification framework. Definitions were developed for each class. The classification framework proposed by the HC DAS and CL consists of 10 pharmacological classes. There are additional subclasses to categorize non-psychoactive substances that are of concern such as cutting agents, precursor chemicals and intermediate reagents.

Validation and considerations

The validation of this framework and substance classification list was supported by our national partners within the Health Portfolio. This list of substance classification has been validated in consultation with pharmacologists and chemists. The following considerations should be taken into account when using the list. A single substance may have multiple effects, and the different effects may be dose dependent. Structural subclasses may fall within several pharmacological classes. Substance classification may be revised in light of new evidence. While the HC DAS and CL classification is based on other classifications, it should be emphasized that each international organization may slightly differ, based on regional specificity.

Figure 1. HC DAS and CL classification framework for psychoactive substances in the illicit drug market

Tap the Pharmacological Classes to see more information.

Table 1. HC DAS and CL classification framework for psychoactive substances in the illicit drug market

Pharmacological class

Definition

Subclass*

Examples

Stimulants

Stimulants increase the activity of the central nervous system. They  induce wakefulness and euphoria. Footnote 1

Some of the substances in this class produce both a stimulant and a hallucinogenic response, sometimes called empathogen-entactogens. Because their  side effects are more similar to stimulants (e.g. increased heart rate, blood pressure, body temperature), these substances are categorized as stimulants in this framework. Footnote 2

Amphetamines / methamphetamines

Lisdexamfetamine; 3,4-methylenedioxyamphetamine (MDA); 3,4-methylenedioxymethamphetamine (MDMA)

Cathinones

3,4-Methylenedioxy-N-methylcathinone; N-Ethyl-heptedrone; 3,4-Methylenedioxypyrovalerone

Ephedrine-type

Ephedrine; Pseudoephedrine; Phenylephrine

Aminoindanes

2-Aminoindane; 5-Methoxy-2-aminoindane; N-Methyl-2-aminoindane

Arylpiperidines and benzylpiperidines

4-Benzylpiperidine; Methylphenidate;  4-Fluoromethylphenidate

Tropanes (stimulant)

Cocaine

Arylpiperazines and benzylpiperazines

Benzylpiperazine; Methylbenzylpiperazine; Trifluoromethylphenylpiperazine

Phenethylamines (stimulant)

Fencamfamin; N-methyl-2-phenylpropan-1-amine (Phenpromethamine)

Other stimulants

Benocyclidine; Bromantane;Aminorex

Hallucinogens

Hallucinogens cause disturbances of perception (visual, olfactory, auditory, tactile) and behavior in ways that cannot be characterized simply as sedative or stimulant effects. Footnote 1 Footnote 3

LSD and analogues

Lysergic acid diethylamide (LSD); 1-propanoyl-lysergic acid diethylamide (1P-LSD); 1-cyclopropionyl-N,N-diethyllysergamide (1cP-LSD)

Tryptamines

5-Methoxy-N,N-diisopropyltryptamine; Psilocybin; N,N-Dimethyltryptamine (DMT)

Tropanes (hallucinogen)

Atropine; Scopolamine

Phenethylamines (hallucinogen)

2C-B; 2C-E; Mescaline

Antipsychotics

Antipsychotics are primarily used to treat psychiatric disorders with or without psychotic symptoms (delusions, hallucinations). Footnote 3 Footnote 4

Atypical  antipsychotics

Aripiprazole; Quetiapine; Olanzapine

Cannabinoids

Cannabinoids are  either plant-derived, synthetic, or semi-synthetic compounds that have affinity for and activity at cannabinoid receptors. They produce a variety of effects, including euphoria (feeling “high”), a sense of well-being, and drowsiness. Footnote 5

Cannabinoids & derivatives

Cannabis; Tetrahydrocannabinol (THC); Cannabidiol (CBD); 9(R)-Hexahydrocannabinol (HHC)

Synthetic cannabinoids and cannabimimetics

N-(1-(aminocarbonyl)-2-methylpropyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA); Nabilone; JWH-018

Dissociatives

Dissociatives produce a mental state in which a person feels out of control and disconnected from their body and environment. Footnote 6

PCP and analogues

Rolicyclidine; Phencyclidine (PCP); 3-Methoxyphencyclidine (3-MeO-PCP)

Ketamine and analogues

2-Fluorodeschloroketamine; Ketamine; Fluorexetamine (FXE)

Other dissociatives

Dextrometorphan; Diphenidine; Salvinorin A

Opioids

Opioids interact with the opioid receptors. They may be natural constituents, derivatives from the opium poppy, or synthetic substances. Opioids produce a variety of effects, including analgesia and euphoria. Footnote 7

Fentanyl and analogues

Fentanyl; para-Fluorofentanyl; Carfentanil

Opiates

Heroin; Oxycodone; Hydromorphone

Nitazenes

Metonitazene; Protonitazene; Isotonitazene

 

Other opioids

Methadone; Tramadol; U-47700

Sedatives/Hypnotics

Sedatives/Hypnotics decrease the activity of the central nervous system. They have a calming effect, can reduce anxiety, and at a higher doses can induce  and maintain sleep. Footnote 8

Benzodiazepines

Alprazolam; Bromazolam; Etizolam

Barbiturates

Butalbital; Pentobarbital; Phenobarbital

GHB and its prodrugs

Gamma-hydroxybutyric acid (GHB); Gamma-butyrolactone (GBL); 1,4-Butanediol

Quinazolinones

Etaqualone; Methaqualone; Methylmethaqualone

Antihistamines (first-generation)

Cyproheptadine; Hydroxyzine; Promethazine

Gabapentinoids

Gabapentin; Pregabalin

Other sedatives/hypnotics

Etomidate; Medetomidine; Xylazine; Zolpidem

Cognitive enhancers

Cognitive enhancers or ‘’Nootropics’’ are a diverse group of substances whose action is thought to improve learning and memory, especially in cases where these functions are impaired. Footnote 9

Nootropics

N-(1-(phenylacetyl)prolyl)glycine ethyl ester (Noopept); Vinpocetine; Phenylpiracetam

Physical performance enhancers

Physical performance enhancers are used to improve or change the physical appearance, and/or increase physical strength and performance in sport. This also includes substances used to enhance sexual behavior and performance. Footnote 10 Footnote 11

Erectile dysfunction drugs

Tadalafil; Sildenafil; Vardenafil

Selective estrogen receptor modulators (SERM)

Clomiphene; Tamoxifen

Selective androgen receptor modulators (SARM)

Andarine; Enobosarm; Ligandrol

Steroids

Metandienone; Stanozolol; Testosterone enanthate

Antidepressants

Antidepressants are used to treat depression and other mental health conditions such as obsessive-compulsive disorder, social phobia, panic disorder, generalized anxiety disorder, and post-traumatic stress disorder. Footnote 12

Selective Serotonin Reuptake Inhibitors (SSRI)

Citalopram; Fluoxetine; Vortioxetine

Serotonin/Norepinephrine Reuptake inhibitors (SNRI)

Duloxetine; Levomilnacipran; Venlafaxine

Atypical Antidepressants

Mirtazapine; Trazodone

Tricyclic Antidepressants (TCA)

Amitriptyline; Amineptine; Doxepin

Other

This class includes cutting agents, precursor chemicals and intermediate reagents, among others, that may have licit or illicit use on their own or formed during production.

Precursors / key intermediates / reagents / by-products

4-Anilino-N-phenethylpiperidine (4-ANPP); α-methyl-3,4-methylenedioxyphenylpropionamide (MMDPPA); 1-Phenyl-2-propanone(P2P)

Cutting agents

Caffeine; Dimethylsulphone; Phenacetin

Muscle relaxants

Cyclobenzaprine; Methocarbamol; Rocuronium

Opioid antagonists

Diprenorphine; Naloxone

Anti-epileptics/Mood stabilizers

Levetiracetam; Topiramate; Valproic acid

* Subclass is a more precise classification based on either "effect", "structure" or "usage" of substances.

Acknowledgments

Additional resources

Download the list of classified substances (.csv) established according to HC DAS and CL Framework.

Contact Information

To submit a request or comment, please contact HC DAS and CL Data Intelligence and Harm Reduction Unit (DIHRU) by email at dascl-info-sadlc@hc-sc.gc.ca.

References

Footnote 1

J. M. Ritter, R. J. Flower, G. Henderson, Y. Kong Loke, D. MacEwan, E. Robinson and J. Fullerton, 'Section 4. Nervous System,' in Rang & Dale's Pharmacology, Elsevier, 2023.

Return to footnote 1 referrer

Footnote 2

H. Kalant, 'The pharmacology and toxicology of ''ecstasy'' (MDMA) and related drugs,' Canadian Medical Association Journal, vol. 165, no. 7, pp. 917-28, 2001.

Return to footnote 2 referrer

Footnote 3

A. L. Halberstadt, 'Recent advances in the neuropsychopharmacology of serotonergic hallucinogens,' Behavioural Brain Research, vol. 277, pp. 99-120, 2015.

Return to footnote 3 referrer

Footnote 4

L. Stevens and K. Chokhawala, 'Antipsychotic Medications,' 26 February 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK519503/. [Accessed 23 May 2024].

Return to footnote 4 referrer

Footnote 5

J. G. Harry, 'Chapter One: Cannabinoids,' in Advances in Neurotoxicology, Elsevier, 2022, pp. 1-48.

Return to footnote 5 referrer

Footnote 6

National Institute on Drug Abuse, U.S., 'Research Report Series: Hallucinogens and Dissociative Drugs,' 2014.

Return to footnote 6 referrer

Footnote 7

T. Yaksh and M. Wallace, 'Chapter 20: Opioids, Analgesia, and Pain Management,' in Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e, McGraw Hill / Medical, 2017.

Return to footnote 7 referrer

Footnote 8

J. A. Trevor, 'Chapter 22: Sedative¬Hypnotic Drugs,' in Basic & Clinical Pharmacology, 14e, K. B.G, Ed., McGraw-Hill Education, 2017.

Return to footnote 8 referrer

Footnote 9

M. Malík and P. Tlustoš, 'Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs,' Nutrients, vol. 14, no. 16, p. 3367, 2022.

Return to footnote 9 referrer

Footnote 10

National Institute on Drug Abuse, 'Anabolic Steroids and Other Appearance and Performance Enhancing Drugs (APEDs),' May 2023. [Online]. Available: https://nida.nih.gov/research-topics/anabolic-steroids. [Accessed 23 May 2024].

Return to footnote 10 referrer

Footnote 11

B. C. Harte, 'Recreational Use of Erectile Dysfunction Medications and ItsAdverse Effects on Erectile Function in Young Healthy Men:The Mediating Role of Confidence in Erectile Ability,' The Journal of Sexual Medecine, vol. 9, no. 7, pp. 1852-1859, July 2012.

Return to footnote 11 referrer

Footnote 12

A. J. Trevor, B. G. Katzung, M. Kruidering-Hall and S. B. Masters, 'Chapter 30. Antidepressants,' in Katzung & Trevor’s Pharmacology: Examination & Board Review, 10e, The McGraw-Hill Companies, 2013.

Return to footnote 12 referrer

Did you find what you were looking for?

What was wrong?

Answers to frequently asked questions can be found in the Understanding the data section!

(Don’t include any personal information. Note that you will not receive a reply.)
Maximum 300 characters

Thank you for your feedback

Date modified: